Concepedia

Anthony W. DeFusco

AW

Statistics

Publications

4

Citations

98

H-Index

4

Active since

2018

Affiliations

ExxonMobil (United States)(Current)

Oragenics (United States)

University of North Texas System

University of Massachusetts Lowell

Anthony W. DeFusco is an author at ExxonMobil (United States) specializing in drug resistance, antimicrobial pharmacokinetics, and drug discovery.

Top concepts

Publications per year

2018–2019

4

Publications

4

Mutacin 1140 Lantibiotic Variants Are Efficacious Against Clostridium difficile Infection

Johan A. Kers, Robert E. Sharp, Anthony W. DeFusco et al. · Frontiers in Microbiology · 2018 · 48 citations · Full text

OG716: Designing a fit-for-purpose lantibiotic for the treatment of Clostridium difficile infections

Johan A. Kers, Anthony W. DeFusco, Jae H. Park et al. · PLoS ONE · 2018 · 22 citations · Full text

, , +17

Pharmacological, Toxicological, and Dose Range Assessment of OG716, a Novel Lantibiotic for the Treatment of <i>Clostridium difficile</i> -Associated Infection

Mark Pulse, Jason Weiss, Johan A. Kers et al. · Antimicrobial Agents and Chemotherapy · 2019 · 15 citations · Full text

Blueprints for the rational design of therapeutic mutacin 1140 variants

Johan A. Kers, Robert E. Sharp, Sheela Muley et al. · Chemical Biology & Drug Design · 2018 · 13 citations

Rows per page

1–4 of 4